Literature DB >> 12034088

A DNA vaccine against foot-and-mouth disease elicits an immune response in swine which is enhanced by co-administration with interleukin-2.

Ho Tsun Wong1, Samuel Chak-Sum Cheng, Fion Wan-Yee Sin, Ella Wai-Ching Chan, Zu Tian Sheng, Yong Xie.   

Abstract

A plasmid DNA vaccine candidate (pCEIS) encoding two foot-and-mouth disease virus (FMDV) VP1 epitopes (amino acid residues 141-160 and 200-213) has been demonstrated to have the ability to elicit both FMDV-specific T cell proliferation and neutralizing antibody against FMD in swine. In this study, the efficiency of the pCEIS DNA vaccine when administrated by intramuscularly injection in swine was confirmed, and the immunogenicity of the pCEIS vaccine candidate was found to be enhanced through co-administration with a newly constructed plasmid (pIL2S) encoding the swine interleukin-2 (IL-2) cDNA. The expression of the pIL2S plasmid was driven by a CMV promotor provided by a pcDNA3.1 vector. Swine IL-2 cDNA was cloned by RT-PCR from swine spleen cells. The pIL2S plasmid was expressed in COS-7 cells after 24 and 96h of transfection in vitro. In an animal trial, results from T cell proliferation assay indicated that the stimulation index (SI) in response to stimulation of FMDV proteins in the swine groups injected with pCEIS plus pIL2S (SI ranging from 9.9 to 15.5) were significantly higher than that with pCEIS alone (SI ranging from 3.3 to 6.6). However, there was no significant difference in FMDV-neutralizing antibody level detected in these two swine groups. Mouse protection tests (MPTs) showed that the blood sera from immunized swine injected with either pCEIS alone or pCEIS plus pIL2S were able to protect suckling mice from FMDV challenge, with protection levels ranging from 10(1) to 10(2) lethal dose 50 (LD(50)) M. In a direct FMDV challenge, all swines immunized with either pCEIS plus pIL2S or with pCEIS alone were challenged with 50LD(50)S (50 x lethal dosage in swine) of FMDV. The animals were fully protected (100%) from the FMD viral challenge. These results suggest that co-administration of the plasmids, pCEIS and pIL2S, enhances of the immunogenicity of the pCEIS DNA vaccine candidate, and both intramuscular injection of pCEIS alone and co-administration of the vaccine candidate with pIL2S can protect the swine from direct FMD challenge.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12034088     DOI: 10.1016/s0264-410x(02)00212-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

Review 1.  Foot-and-mouth disease.

Authors:  Marvin J Grubman; Barry Baxt
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

2.  Co-expression of the Bcl-xL antiapoptotic protein enhances the induction of Th1-like immune responses in mice immunized with DNA vaccines encoding FMDV B and T cell epitopes.

Authors:  Sultan Gülçe İz; Mert Döşkaya; Belen Borrego; Fernando Rodriguez; Yüksel Gürüz; Ismet Deliloğlu Gürhan
Journal:  Vet Res Commun       Date:  2013-03-13       Impact factor: 2.459

3.  DNA fragment encoding human IL-1beta 163-171 peptide enhances the immune responses elicited in mice by DNA vaccine against foot-and-mouth disease.

Authors:  H J Shao; L Chen; Y B Su
Journal:  Vet Res Commun       Date:  2005-01       Impact factor: 2.459

4.  Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice.

Authors:  Hui Hu; Xinya Lu; Ling Tao; Bingke Bai; Zhenfeng Zhang; Yao Chen; Fangliang Zheng; Jianjun Chen; Ze Chen; Hanzhong Wang
Journal:  Clin Vaccine Immunol       Date:  2007-05-09

5.  Immunization of DNA vaccine encoding C3d-VP1 fusion enhanced protective immune response against foot-and-mouth disease virus.

Authors:  Huiying Fan; Tiezhu Tong; Huanchun Chen; Aizhen Guo
Journal:  Virus Genes       Date:  2007-05-12       Impact factor: 2.332

6.  Comparison of immune responses against FMD by a DNA vaccine encoding the FMDV/O/IRN/2007 VP1 gene and the conventional inactivated vaccine in an animal model.

Authors:  Farahnaz Motamedi Sedeh; Hoorieh Soleimanjahi; AmirReza Jalilian; Homayoon Mahravani
Journal:  Virol Sin       Date:  2012-09-21       Impact factor: 4.327

7.  Enhanced immune response of DNA vaccine (VP1-pCDNA) adsorbed on cationic PLG for foot and mouth disease in guinea pigs.

Authors:  Sumit Choudary; P Ravikumar; C Ashok Kumar; V V S Suryanarayana; G R Reddy
Journal:  Virus Genes       Date:  2008-05-31       Impact factor: 2.332

Review 8.  DNA vaccines in veterinary use.

Authors:  Laurel Redding; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2009-09       Impact factor: 5.217

9.  Enhanced immune response with foot and mouth disease virus VP1 and interleukin-1 fusion genes.

Authors:  Jong Hyeon Park; Sun Jin Kim; Jae Ku Oem; Kwang Nyeong Lee; Yong Joo Kim; Soo Jeong Kye; Jee Yong Park; Yi Seok Joo
Journal:  J Vet Sci       Date:  2006-09       Impact factor: 1.672

10.  A review of vaccine development and research for industry animals in Korea.

Authors:  Nak-Hyung Lee; Jung-Ah Lee; Seung-Yong Park; Chang-Seon Song; In-Soo Choi; Joong-Bok Lee
Journal:  Clin Exp Vaccine Res       Date:  2012-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.